Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

John F. Sheridan net worth and biography

John Sheridan Biography and Net Worth

CEO of Tandem Diabetes Care

Mr. Sheridan has served on our board of directors since June 2019 and as our President and Chief Executive Officer since March 2019. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining us, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan serves as a director of Acutus Medical, Inc. (Nasdaq: AFIB), an arrhythmia management company. Mr. Sheridan holds a BS in Chemistry from the University of West Florida and an MBA from Boston University.

What is John F. Sheridan's net worth?: The estimated net worth of John F. Sheridan is at least $361,182.78 as of May 9th, 2022. Mr. Sheridan owns 10,058 shares of Tandem Diabetes Care stock worth more than $361,183 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Sheridan may own. Additionally, Mr. Sheridan receives an annual salary of $988,350.00 as CEO at Tandem Diabetes Care. Learn More about John F. Sheridan's net worth.
How old is John F. Sheridan?: Mr. Sheridan is currently 69 years old. There are 8 older executives and no younger executives at Tandem Diabetes Care. Learn More on John F. Sheridan's age.
What is John F. Sheridan's salary?: As the CEO of Tandem Diabetes Care, Inc., Mr. Sheridan earns $988,350.00 per year. Learn More on John F. Sheridan's salary.
How do I contact John F. Sheridan?: The corporate mailing address for Mr. Sheridan and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on John F. Sheridan's contact information.
Has John F. Sheridan been buying or selling shares of Tandem Diabetes Care?: John F. Sheridan has not been actively trading shares of Tandem Diabetes Care over the course of the past ninety days. Most recently, on Monday, May 9th, John F. Sheridan bought 2,500 shares of Tandem Diabetes Care stock. The stock was acquired at an average cost of $69.90 per share, with a total value of $174,750.00. Following the completion of the transaction, the chief executive officer now directly owns 10,058 shares of the company's stock, valued at $703,054.20. Learn More on John F. Sheridan's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 1 times. They purchased a total of 532 shares worth more than $12,363.68. In the last twelve months, insiders at the medical device company sold shares 3 times. They sold a total of 25,000 shares worth more than $858,400.00. The most recent insider tranaction occured on November, 20th when Director Kim D Blickenstaff sold 10,000 shares worth more than $300,000.00. Insiders at Tandem Diabetes Care own 2.2% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 11/20/2024.

John F. Sheridan Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/9/2022	Buy	2,500	$69.90	$174,750.00	10,058
10/13/2020	Sell	15,000	$121.31	$1,819,650.00	18,756
9/16/2020	Sell	401	$110.37	$44,258.37	13,355
8/3/2020	Sell	33,200	$102.21	$3,393,372.00	5,423
11/25/2019	Sell	462	$70.00	$32,340.00	2,963
9/6/2019	Sell	9,538	$70.03	$667,946.14	12,039
2/27/2019	Sell	20,000	$62.03	$1,240,600.00	18,999
1/25/2019	Sell	20,000	$45.26	$905,200.00	20,666
1/2/2019	Sell	20,788	$35.76	$743,378.88
8/1/2016	Sell	15,000	$6.52	$97,800.00	22,763
5/2/2016	Sell	2,000	$10.61	$21,220.00	7,295
4/22/2016	Sell	2,000	$10.00	$20,000.00	7,295
3/7/2016	Sell	4,000	$10.01	$40,040.00	9,295
12/1/2015	Sell	2,000	$10.14	$20,280.00	4,084
11/2/2015	Sell	4,000	$10.00	$40,000.00	4,084
9/14/2015	Sell	2,000	$12.51	$25,020.00	4,084
5/1/2015	Sell	2,000	$13.72	$27,440.00
4/1/2015	Sell	2,000	$12.47	$24,940.00
2/2/2015	Sell	2,000	$12.06	$24,120.00
1/2/2015	Sell	2,000	$12.75	$25,500.00
12/1/2014	Sell	2,000	$13.55	$27,100.00
11/3/2014	Sell	2,000	$16.00	$32,000.00
10/1/2014	Sell	2,000	$13.07	$26,140.00
9/2/2014	Sell	2,000	$13.99	$27,980.00
8/1/2014	Sell	2,000	$15.04	$30,080.00
7/1/2014	Sell	2,000	$16.42	$32,840.00
6/18/2014	Sell	2,000	$16.75	$33,500.00

John F. Sheridan Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $35.91

$32.46

$36.31

50 Day Range

MA: $32.34

$27.34

$37.61

2 Week Range

Now: $35.91

$21.85

$53.69

Volume

4,334,886 shs

Average Volume

1,585,730 shs

Market Capitalization

$2.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.

John Sheridan Biography and Net Worth

What is John F. Sheridan's net worth?

How old is John F. Sheridan?

What is John F. Sheridan's salary?

How do I contact John F. Sheridan?

Has John F. Sheridan been buying or selling shares of Tandem Diabetes Care?

Who are Tandem Diabetes Care's active insiders?

Are insiders buying or selling shares of Tandem Diabetes Care?